Grant: Catalyst Grant: Cannabis Research in Urgent Priority Areas
University of Calgary
$125,000.00
Cannabis for the Prophylactic Treatment of Migraine: a randomized double-blind placebo-controlled clinical trial
EF 2018-19
Résumé
Many patients with pain conditions, including those suffering from migraine headaches, have tried or are curious about medical cannabis as a possible treatment for their pain. Unfortunately, strong studies do not yet exist in this area. There are few data on how effective or safe medical cannabis truly is. We are a group of researchers at the University of Calgary interested in studying the effect of Cannabidiol (CBD), a component of medical cannabis, on reducing migraine frequency and related conditions such as anxiety and depression. The study we propose will study CBD at 2 different doses and compare it to placebo. This will be done in such a way that participants and researchers will not be aware of which group a given participant is assigned to. Participants will undergo screening to ensure eligibility for the study and then be randomly assigned to one of the groups. Treatment will be provided for 3 months. Data will be collected before the start of the study and then again at 3 month intervals for one year. The data collected will then be analyzed to determine if CBD is safe and if it is helpful in reducing migraine frequency. The proposed study would be one of the first to compare CBD to placebo and study its effectiveness and safety for the treatment of migraine.
Programme
Catalyst Grant: Cannabis Research in Urgent Priority Areas
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
392253
Name
Amoozegar Farnaz
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Cannabis Research in Urgent Priority Areas
Projecttitle
Cannabis for the Prophylactic Treatment of Migraine: a randomized double-blind placebo-controlled clinical trial
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$125,000
Cihrequipment2
$0
Programname2
Catalyst Grant: Cannabis Research in Urgent Priority Areas
Keyworddelim
Cannabis; Migraine; Randomized Controlled Trial
Abstract
Many patients with pain conditions, including those suffering from migraine headaches, have tried or are curious about medical cannabis as a possible treatment for their pain. Unfortunately, strong studies do not yet exist in this area. There are few data on how effective or safe medical cannabis truly is. We are a group of researchers at the University of Calgary interested in studying the effect of Cannabidiol (CBD), a component of medical cannabis, on reducing migraine frequency and related conditions such as anxiety and depression. The study we propose will study CBD at 2 different doses and compare it to placebo. This will be done in such a way that participants and researchers will not be aware of which group a given participant is assigned to. Participants will undergo screening to ensure eligibility for the study and then be randomly assigned to one of the groups. Treatment will be provided for 3 months. Data will be collected before the start of the study and then again at 3 month intervals for one year. The data collected will then be analyzed to determine if CBD is safe and if it is helpful in reducing migraine frequency. The proposed study would be one of the first to compare CBD to placebo and study its effectiveness and safety for the treatment of migraine.
Competitiondate
201810
Approvedterm2
1 yr 0 mth
Pinamesdelim
Amoozegar, Farnaz
Approvedterm
1 an 0 mois
Cihrcontribution2
Major Initiatives #3~ $125,000~ $0~